Serum and tissue biomarkers associated with CRESS and STAR response to B-cell targeted therapy in TRACTISS trial of Sjogren's syndrome.
Elena PontariniE SciaccaF ChowdhuryS GrigoriadouF RivelleseW J Murray-BrownDavide LucchesiL Fossati-JimackA NervianiWlodzimierz J KrzyzosiakG M GhirardiC GiacomassiPaul EmeryW F NgN SutcliffeColin C EverettC FernandezA R TappuniR SerorX MarietteR PorcherG CavallaroA PulvirentiGwenny M VerstappenLisette de WolffS ArendsH BootsmaMyles J LewisCostantino PitzalisS J BowmanM Bombardierinull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Rituximab modulates both peripheral and SG inflammation, preventing the deterioration of exocrine function linked with functional and metabolic restoration of the glandular epithelium. Response assessed by newly developed cCRESS and STAR criteria was associated with differential modulation of peripheral and SG biomarkers, emerging as novel tools for patient stratification.